# GLACEUM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glaceum

- Industry: Pharmaceuticals
- Headquarters: Gyeonggi-do, South Korea
- Website: www.glaceum.com
- Total disclosed funding: $25M
- Latest round: Series D (Nov 29, 2019)
- Investors on record: 6

## About

Based in South Korea, and founded in 2014, GLACEUM, INC. develops therapeutic drugs for retinal and inflammatory diseases and also treats obesity. In June 2021, the firm raised KRW 12 billion in pre-IPO funding from investors Korea Development Bank and J-Curve Investment Co., Ltd. Individual investors also participated in the round. The transaction values the company at KRW 200 billion post-money.

The company offer metabolic syndrome drug and therapy for the treatment of metabolic diseases including nonalcoholic steatohepatitis (NASH). The business specializes in treating conditions including obesity, diabetes, and fatty liver by focusing on the mitochondria, a crucial organelle that produces energy and synthesizes important chemicals associated with inflammation.

## Funding rounds

- Series D, Nov 29, 2019, $5.3M — Hana Bank, Korea Investment & Securities, Korea Securities Finance Corporation
- Series C, Apr 6, 2019, $11M — Korea Investment & Securities, Industrial Bank of Korea, NH Investment & Securities
- Series B, Sep 20, 2018, $2.6M — Hana Bank, Industrial Bank of Korea, NH Investment & Securities
- Series A, Jun 1, 2016, $5.7M — QUAD Investment Management

## Investors

- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series A
- Hana Bank — Series B, Series D
- Industrial Bank of Korea — Series B, Series C
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B, Series C
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C, Series D
- Korea Securities Finance Corporation — Series D